Earnings / Pharma
Johnson & Johnson Beats Q3 Estimates as Tremfya Surges, but a Talc Charge Cuts Reported EPS to $0.09
J&J posted $25.4 billion in Q3 sales and $2.59 in adjusted EPS, both ahead of estimates, and raised 2026 guidance — while a one-time talc charge cut reported EPS to $0.09.